Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
Front Cardiovasc Med
.
2022 Aug 4:9:987025.
doi: 10.3389/fcvm.2022.987025.
eCollection 2022.
Authors
Lixin Du
1
,
Jiao Qin
1
,
Dengchuan Wang
2
,
Yunhui Zhao
1
,
Ning Xu
1
,
Chaowen Wu
3
Affiliations
1
Department of Medical Imaging, Shenzhen Longhua District Central Hospital, Shenzhen, China.
2
Office of Medical Ethics, Shenzhen Longhua District Central Hospital, Shenzhen, China.
3
Department of Endocrinology, Shenzhen Longhua District Central Hospital, Shenzhen, China.
PMID:
35990975
PMCID:
PMC9386073
DOI:
10.3389/fcvm.2022.987025
No abstract available
Keywords:
GLP-1RAs; SGLT 2 inhibitors; cardiovascular; death; renal; type 2 diabetes.
Publication types
Comment